NEPRILYSIN INHIBITORS (ARNI) IN THE TREATMENT OF CHRONIC HEART FAILURE — A SYSTEMATIC REVIEW AND CRITICAL APPRAISAL OF THE EVIDENCE
Abstract
Angiotensin receptor–neprilysin inhibitors (ARNI), with sacubitril/valsartan as the prototypical agent, have fundamentally transformed the pharmacological treatment paradigm of chronic heart failure (HF) [6,11,36,47,48,49,50]. This systematic review synthesizes the available clinical evidence, with a particular focus on the therapeutic efficacy of ARNI across the full continuum of left ventricular ejection fraction [3,4,17,50]. In patients with heart failure with reduced ejection fraction (HFrEF), pivotal randomized trials have consistently demonstrated the superiority of ARNI over conventional angiotensin-converting enzyme inhibitors in lowering cardiovascular mortality and HF-related hospitalizations, while also promoting favorable reverse myocardial remodeling [2,9,10,11,18,26,30,39,41,43,44,49]. In contrast, among individuals with preserved or mildly reduced ejection fraction, the principal clinical benefit is reduction in recurrent HF hospitalizations, with numerically greater treatment effects reported in women [1,3,7,18,23]. In addition, sacubitril/valsartan exhibits clinically relevant renoprotective effects and a favorable safety profile in complex patient populations, including those with diabetes mellitus or advanced chronic kidney disease [4,10,11,18]. Contemporary clinical guidelines position ARNI as a cornerstone of quadruple guideline-directed medical therapy, recommending early initiation during hospitalization and proactive dose up-titration to optimize clinical outcomes [7,8,11,13,21,31,47,48,49,50]. Addressing barriers to implementation—such as treatment-related hypotension and therapeutic inertia—remains essential to reduce the considerable global burden of heart failure [5,7,28,29,34,38].
References
Peikert, A., Vaduganathan, M., Claggett, B. L., Kulac, I. J., Litwin, S., Zile, M., Desai, A. S., Jhund, P. S., Butt, J. H., Lam, C. S. P., Martinez, F., Van Veldhuisen, D. J., Zannad, F., Rouleau, J., Lefkowitz, M., McMurray, J. J. V., Solomon, S. D., & Packer, M. (2025). Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial. European heart journal, 46(25), 2372–2390. https://doi.org/10.1093/eurheartj/ehaf057
Cho, D. H., Choi, J., Youn, J. C., Kim, M. N., Lee, C. J., Son, J. W., & Yoo, B. S. (2025). Angiotensin receptor-neprilysin inhibitor adherence and outcomes in heart failure with reduced ejection fraction. ESC heart failure, 12(1), 603–612. https://doi.org/10.1002/ehf2.15117
Kondo, T., Jhund, P. S., Anand, I. S., Claggett, B. L., Desai, A. S., Docherty, K. F., Lam, C. S. P., Lefkowitz, M. P., Maggioni, A. P., Martinez, F. A., Redfield, M. M., Rouleau, J. L., Van Veldhuisen, D. J., Zannad, F., Zile, M. R., Packer, M., Solomon, S. D., & McMurray, J. J. V. (2025). Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF. JACC. Heart failure, 13(6), 927–939. https://doi.org/10.1016/j.jchf.2024.12.010
Jung, M. H., Cho, D. H., Choi, J., Kim, M. N., Lee, C. J., Son, J. W., Kim, Y., Youn, J. C., & Yoo, B. S. (2025). Angiotensin receptor-neprilysin inhibitors in concurrent heart failure with reduced ejection fraction and kidney failure. ESC heart failure, 12(5), 3405–3415. https://doi.org/10.1002/ehf2.15359
Di Pietro, G., Improta, R., Severino, P., D'Amato, A., Birtolo, L. I., De Filippo, O., Lattanzio, A., De Cristofaro, R., Galardo, G., D'Ascenzo, F., Badagliacca, R., Sardella, G., Volterrani, M., Fedele, F., Vizza, C. D., & Mancone, M. (2025). The in-hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta-analysis. ESC heart failure, 12(2), 998–1012. https://doi.org/10.1002/ehf2.15082
Karuna, N., Kerrigan, L., Edgar, K., Ledwidge, M., McDonald, K., Grieve, D. J., & Watson, C. J. (2025). Sacubitril/Valsartan attenuates progression of diabetic cardiomyopathy through immunomodulation properties: an opportunity to prevent progressive disease. Cardiovascular diabetology, 24(1), 206. https://doi.org/10.1186/s12933-025-02741-5
Nouhravesh, N., Gunn, A. H., Cyr, D., Hernandez, A. F., Morrow, D. A., Velazquez, E. J., Ward, J. H., Sarwat, S., Sharma, K., Williamson, K. M., Starling, R. C., Lepage, S., Zieroth, S., Solomon, S. D., & Mentz, R. J. (2025). Sacubitril/valsartan versus valsartan initiation in patients naïve to renin-angiotensin system inhibitors: Insights from PARAGLIDE-HF. European journal of heart failure, 27(8), 1418–1425. https://doi.org/10.1002/ejhf.3579
Rung, J. M., Barrett, T. S., LeJeune, K., Richards, S. B., Raina, A., & Sinoway, L. (2025). Dosing patterns and dose effects of sacubitril/valsartan: A claims-based retrospective cohort study. PloS one, 20(3), e0320216. https://doi.org/10.1371/journal.pone.0320216
León-Román, J., Azancot, M. A., Marouco, C., Patricio-Liebana, M., Zamora, J. I., Ramos Terrades, N., Toapanta, N., Núñez-Delgado, S., Mendez Fernandez, A. B., & Soler, M. J. (2025). A New Era in the Management of Cardiorenal Syndrome: The Importance of Cardiorenal Units. Cardiorenal medicine, 15(1), 174–183. https://doi.org/10.1159/000543294
Cikes, M., Brugts, J. J., Claggett, B., Jorde, U. P., Milicic, D., Planinc, I., Ruschitzka, F., Uriel, N., Kulac, I., Jakus, N., Loncaric, F., Puskaric, F., Sipus, D., Gasparovic, H., Rubis, P., van Laake, L. W., Rudez, I., Hegarova, M., Sestan, G., Wisniowska-Smialek, S., … Solomon, S. D. (2025). Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy: Primary Results of the ENVAD-HF Trial. JACC. Heart failure, 13(11), 102657. https://doi.org/10.1016/j.jchf.2025.102657
Kato, T., Nakano, Y., Yasukawa, N., Oonishi, M., & Hamada, Y. (2025). Dose-dependent renoprotective effects of sacubitril/valsartan in heart failure: a retrospective study. Renal failure, 47(1), 2538830. https://doi.org/10.1080/0886022X.2025.2538830
Prausmüller, S., Wurm, R., Ponleitner, M., Stögmann, E., Hülsmann, M., & Pavo, N. (2025). Effect of Initiation With Sacubitril/valsartan on Blood Neurodegeneration Markers in HFrEF. Journal of cardiac failure, 31(6), 967–971. https://doi.org/10.1016/j.cardfail.2025.01.021
Arzhangzadeh, A., Nikoo, M. H., Haghjoo, M., Rasekh, F., Shojaei, S., Mousavi, A., Nozhat, S., Narimani-Javid, R., Bazroodi, H., Neisi, S., Mojibpour, M., Abedini, M., Eslamzadeh, S., Drissi, H. B., & Shafiei, S. (2025). The Effect of Sacubitril/Valsartan on Supraventricular and Ventricular Arrhythmias in Patients With Heart Failure. Annals of noninvasive electrocardiology: the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, 30(3), e70081. https://doi.org/10.1111/anec.70081
Ingimarsdóttir, I. J., Vishram-Nielsen, J. K. K., Einarsson, H., Goldfeder, S., Mewton, N., Barasa, A., Basic, C., Oerlemans, M. I. F. J., Niederseer, D., Shchendrygina, A., Gustafsson, F., Ruschitzka, F., Kida, K., Mohty, D., Rakotonoel, R. R., Tun, H. N., Hrafnkelsdóttir, T. J., & Saldarriaga, C. (2025). Diagnostic and therapeutic practice for HFpEF across continents and regions: An international survey. ESC heart failure, 12(1), 487–496. https://doi.org/10.1002/ehf2.15084
Mathur, R., Baroopal, A., Chaudhary, C. R., Hakim, A., & Verma, M. (2025). Efficacy of Angiotensin Receptor Neprilysin Inhibitor (ARNI) in right ventricular systolic dysfunction and preserved LV ejection fraction: A randomized clinical trial. Indian heart journal, 77(1), 42–44. https://doi.org/10.1016/j.ihj.2025.01.002
Zhao, Y. M., Luo, J. T., Pang, K. F., Feng, Y., Tan, J. P., Liu, M., & Lin, Z. H. (2025). Clinical efficacy of sacubitril/valsartan combined with cardiac rehabilitation in patients with heart failure after acute myocardial infarction: a single-center randomized trial. BMC cardiovascular disorders, 25(1), 246. https://doi.org/10.1186/s12872-025-04682-z
Albertini, M., Waldmann, V., David, P., Barat, A., Legendre, A., Chaussade, A. S., Iserin, L., & Ladouceur, M. (2025). Safety and Efficacy of Dapagliflozin in Patients With Systemic Right Ventricular Dysfunction: DAPA-SRV Trial.
Journal of the American Heart Association, 14(11), e040302. https://doi.org/10.1161/JAHA.124.040302
Chimura, M., Butt, J. H., Matsumoto, S., McMurray, E. G. M., Henderson, A. D., Talebi, A., Desai, A. S., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Solomon, S. D., Swedberg, K., Zile, M. R., Packer, M., Jhund, P. S., & McMurray, J. J. V. (2025). Comprehensive Analysis of the Effects of Sacubitril/Valsartan According to Sex Among Patients With Heart Failure and Reduced Ejection Fraction in PARADIGM-HF. Journal of the American Heart Association, 14(9), e038249. https://doi.org/10.1161/JAHA.124.038249
Mizutani, H., Fujimoto, N., Nakamori, S., Kokawa, T., Ishiyama, M., Omori, T., Moriwaki, K., Sato, Y., Goto, I., Sugiura, E., Ishida, M., Kurita, T., Koji, T., Okamoto, R., Murashima, S., Tanigawa, T., Sakuma, H., & Dohi, K. (2025). Effects of Sacubitril/Valsartan on Myocardial Tissue in Heart Failure With Left Ventricular Ejection Fraction Below 50. Circulation journal: official journal of the Japanese Circulation Society, 89(7), 901–911. https://doi.org/10.1253/circj.CJ-24-0934
Sadasivan, C., Gagnon, L. R., Hazra, D., Wang, K., Youngson, E., Thomas, J., Chan, A. Y. M., Paterson, D. I., McAlister, F. A., Dzwiniel, T., Tymchak, W., Christian, S., & Oudit, G. Y. (2025). Early genetic screening and cardiac intervention in patients with cardiomyopathies in a multidisciplinary clinic. ESC heart failure, 12(3), 1942–1955. https://doi.org/10.1002/ehf2.15202
Sadasivan, C., Gagnon, L. R., Hazra, D., Wang, K., Youngson, E., Thomas, J., Chan, A. Y. M., Paterson, D. I., McAlister, F. A., Dzwiniel, T., Tymchak, W., Christian, S., & Oudit, G. Y. (2025). Early genetic screening and cardiac intervention in patients with cardiomyopathies in a multidisciplinary clinic. ESC heart failure, 12(3), 1942–1955. https://doi.org/10.1002/ehf2.15202
Anker, S. D., Friede, T., Butler, J., Talha, K. M., Placzek, M., Diek, M., Nosko, A., Stas, A., Kluge, S., Jarczak, D., Deheer, G., Rybczynski, M., Bayes-Genis, A., Edelmann, F., Filippatos, G., Hasenfuß, G., Haverkamp, W., Lainscak, M., Landmesser, U., Macdougall, I. C., … Karakas, M. (2025). Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure (FAIR-HF2-DZHK05) trial: Baseline characteristics and comparison to other relevant clinical trials. European journal of heart failure, 27(8), 1436–1443. https://doi.org/10.1002/ejhf.3658
Karamchand, S., Chipamaunga, T., Naidoo, P., Naidoo, K., Rambiritch, V., Ho, K., Chilton, R., McMahon, K., Leisegang, R., Weich, H., & Hassan, K. (2025). Novel Versus Conventional Sequencing of β-Blockers, Sodium/Glucose Cotransportor 2 Inhibitors, Angiotensin Receptor-Neprilysin Inhibitors, and Mineralocorticoid Receptor Antagonists in Stable Patients With Heart Failure With Reduced Ejection Fraction (NovCon Sequencing Study): Protocol for a Randomized Controlled Trial. JMIR research protocols, 14, e44027. https://doi.org/10.2196/44027
Chen, Q. F., Lu, Y., Katsouras, C. S., Peng, Y., Sun, J., Li, M., Liu, C., Yao, H., Lian, L., Feng, X., Lin, W. H., & Zhou, X. D. (2025). Characteristics, outcomes and the necessity of continued guideline-directed medical therapy in patients with heart failure with improved ejection fraction. Annals of medicine, 57(1), 2442535 https://doi.org/10.1080/07853890.2024.2442535
Jung, K., Kim, J. H., Bea, S., Ko, H. Y., You, S. C., Choi, E. K., Lee, S., Lim, M., Kim, G. J., Kang, D. Y., & Shin, J. Y. (2025). Association between sacubitril/valsartan and risk of dementia in patients with heart failure: a nationwide cohort study. European heart journal. Cardiovascular pharmacotherapy, 11(5), 412–421. https://doi.org/10.1093/ehjcvp/pvaf024
Shaddy, R., Gong, J., Garito, T., Solar-Yohay, S., Zhang, S., Prescott, M. F., Bonnet, D., Kantor, P. F., Burch, M., Mao, C., Cilliers, A., Canter, C., Law, Y., Grutter, G., Wang, J. K., Jeewa, A., Rossano, J., & PANORAMA‐HF investigators (2025). Association between NT-proBNP changes and clinical outcomes in paediatric patients with heart failure: Insights from PANORAMA-HF and PARADIGM-HF. ESC heart failure, 12(4), 3042–3052. https://doi.org/10.1002/ehf2.15326
Shimizu, K., Tabata, T., Iwakawa, M., Ikeda, Y., Ikeda, T., Nonaka, S., Sato, S., Nakagami, T., Mikamo, H., & Kinoshita, T. (2025). Potential Effects of Sacubitril/Valsartan on the Cardio-ankle Vascular Index in Hypertensive Patients. Internal medicine (Tokyo, Japan), 64(10), 1470–1475. https://doi.org/10.2169/internalmedicine.4041-24
Lu, H., Inciardi, R. M., Abanda, M., Shah, A. M., Cikes, M., Claggett, B. L., Prasad, N., Lam, C. S. P., Redfield, M., McMurray, J. J. V., Pfeffer, M. A., Solomon, S. D., Hegde, S. M., & Skali, H. (2025). Multiparametric Assessment of Right Ventricular Dysfunction in Heart Failure: An Analysis From PARAGON-HF. Journal of the American Heart Association, 14(1), e037380. https://doi.org/10.1161/JAHA.124.037380
Pastore, M. C., Mandoli, G. E., Giannoni, A., Ginetti, F. R., Correale, M., Brunetti, N. D., Guaricci, A. I., Piscitelli, L., Degiovanni, A., Patti, G., Malagoli, A., Moderato, L., Carluccio, E., Marino, P. N., Emdin, M., & Cameli, M. (2025). Right ventricular strain predicts outcome in patients receiving sacubitril/valsartan: A sub-analysis of DISCOVER-ARNI. ESC heart failure, 12(4), 2878–2886. https://doi.org/10.1002/ehf2.15297
Solano, S., Yang, M., Tolomeo, P., Kondo, T., Shen, L., Jhund, P. S., Anand, I. S., Desai, A. S., Lam, C. S. P., Maggioni, A. P., Martinez, F. A., Rouleau, J. L., Vaduganathan, M., van Veldhuisen, D. J., Zannad, F., Zile, M. R., Packer, M., Solomon, S. D., & McMurray, J. J. V. (2025). Clinical Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction and With Reduced Ejection Fraction According to the Prognostic Nutritional Index: Findings From PARADIGM-HF and PARAGON-HF. Journal of the American Heart Association, 14(1), e037782. https://doi.org/10.1161/JAHA.124.037782
Möckel, M., Pudasaini, S., Feldmann, K., Baberg, H. T., Levenson, B., Malzahn, J., Mansky, T., Michels, G., Günster, C., & Jeschke, E. (2025). Prescription of guideline-directed medical therapy in heart failure: impact on mortality and readmission. ESC heart failure, 12(4), 2791–2802. https://doi.org/10.1002/ehf2.15280
Amir, O., Elbaz-Greener, G., Carasso, S., Claggett, B., Barbarash, O., Zaman, A., Christersson, C., Kiatchoosakun, S., Anonuevo, J., Opolski, G., Vaghaiwalla, M. F., van der Meer, P., Zhou, Y., Mann, D. L., Kober, L., Steg, G., Jering, K., Kulac, I., De Pasquale, C. G., McMurray, J. J. V., … PARADISE‐MI Investigators and Committees (2025). Association between body mass index and clinical outcomes in patients with acute myocardial infarction and reduced systolic function: Analysis of PARADISE-MI trial data. European journal of heart failure, 27(3), 558–565. https://doi.org/10.1002/ejhf.3542
Takahashi, T., Kusunose, K., Imai, T., Furukawa, Y., Okada, T., Kadokami, T., Kanzaki, Y., Matsuda, H., Mizukoshi, K., Kida, K., Matsue, Y., Sata, M., Tanaka, A., & Node, K. (2025). Impact of early in-hospital initiation of sacubitril/valsartan on left ventricular reverse remodelling in acute heart failure. European heart journal. Cardiovascular pharmacotherapy, 11(7), 565–573. https://doi.org/10.1093/ehjcvp/pvaf061
Bhatt, A. S., Vaduganathan, M., Jena, B. P., Suminska, S., Eid, C., Schwende, H., & Senni, M. (2025). Real-world comparative effectiveness of sacubitril/valsartan versus RAS inhibition alone in patients with de novo heart failure. ESC heart failure, 12(3), 1682–1692. https://doi.org/10.1002/ehf2.15183
Chedid El Helou, M., Nandar, P. P., Tereshchenko, L. G., Jacob, M., Bhat, P., Vest, A. R., Bhattacharya, S., Hsich, E., Collier, P., Tang, W. H. W., Soltesz, E., Tong, M. Z., Starling, R. C., & Martyn, T. (2025). Factors associated with the use of guideline-directed medical therapy in patients with left ventricular assist device. European journal of heart failure, 27(4), 650–655. https://doi.org/10.1002/ejhf.3591
Nishikimi, T., Nakagawa, Y., Miyamoto, S., Kanamori, T., Inazumi, H., Yanagisawa, H., Moriuchi, K., Kinoshita, H., Tamamura, Y., Takahama, H., Minamino, N., & Ono, K. (2025). Responses of B-type natriuretic peptide (BNP), mature BNP and proBNP to sacubitril/valsartan differs between responders and non-responders. Open heart, 12(1), e002990. https://doi.org/10.1136/openhrt-2024-002990
Neijenhuis, R. M. L., Nederend, M., van Groningen, A. E., Jongbloed, M. R. M., Vliegen, H. W., Jukema, J. W., Kiès, P., & Egorova, A. D. (2025). Sacubitril/valsartan is associated with improvements in quality of life in adult congenital heart disease patients with systemic right ventricular failure. Open heart, 12(1), e003009. https://doi.org/10.1136/openhrt-2024-003009
Iwasaki, E., Kohyama, N., Inamoto, M., Nagao, M., Sunaga, T., Suzuki, H., Ebato, M., & Kogo, M. (2025). Factors Associated With Sacubitril/Valsartan Continuation and the Methods of Combining Heart Failure Medications in Patients With Heart Failure. The Annals of pharmacotherapy, 59(4), 301–310. https://doi.org/10.1177/10600280241277354
Hu, Y., Ma, F., Hu, M., Shi, B., Pan, D., & Ren, J. (2025). Development and validation of a machine learning model to predict the risk of readmission within one year in HFpEF patients: Short title: Prediction of HFpEF readmission. International journal of medical informatics, 194, 105703. https://doi.org/10.1016/j.ijmedinf.2024.105703
Armentaro, G., Cassano, V., Magurno, M., Pastura, C. A., Divino, M., Severini, G., Martire, D., Miceli, S., Maio, R., Mazza, E., Montalcini, T., Pujia, A., & Sciacqua, A. (2025). Gliflozines as add-on to Arni in echocardiographic, sarcopenic and oxidative stress parameters in elderly patients with chronic heart failure. Aging clinical and experimental research, 37(1), 158. https://doi.org/10.1007/s40520-025-03049-w
Dini, F. L., Cioffi, G., Carluccio, E., Ghio, S., Pugliese, N. R., Correale, M., Dattilo, G., Palazzuoli, A., & Working Group on Heart Failure of the Italian Society of Cardiology (2025). Insights into the Benefits of Reverse Remodeling from an Echocardiographic Pressure/Volume Loop Model in Patients With Heart Failure Treated With Sacubitril/Valsartan. The American journal of cardiology, 254, 21–29. https://doi.org/10.1016/j.amjcard.2025.06.012
Laborante, R., Delvinioti, A., Tudor, A. M., Lenkowicz, J., Iacomini, C., Iaconelli, A., Paglianiti, D. A., Galli, M., Rodolico, D., Patarnello, S., Restivo, A., Ciliberti, G., Rizzo, G., Bianchini, E., Busti, M., Sensini, L., Valentini, V., Scambia, G., Gasbarrini, A., Crea, F., … D'Amario, D. (2025). Temporal trends in guideline-recommended medical therapy after an acute heart failure decompensation event: an observational analysis from Generator Heart Failure DataMart. BMJ open, 15(2), e088998. https://doi.org/10.1136/bmjopen-2024-088998
Fumarulo, I., Pasquini, A., La Vecchia, G., Pellizzeri, B., Sten, A., Garramone, B., Vaccarella, M., Ravenna, S. E., Lombardo, A., Burzotta, F., Pitocco, D., & Aspromonte, N. (2025). Evaluation of the Effects of the Sodium-Glucose Cotransporter 2 Inhibitors and Sacubitril/Valsartan Combined Therapy in Patients with HFrEF: An Echocardiographic Study. International journal of molecular sciences, 26(12), 5651. https://doi.org/10.3390/ijms26125651
Shahim, A., Linde, C., Savarese, G., Dahlström, U., Lund, L. H., & Hage, C. (2025). Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry. European journal of heart failure, 27(3), 421–431. https://doi.org/10.1002/ejhf.3565
Zhu, T., & Song, Y. (2025). Efficacy of Sacubitril/Valsartan Combined With Metoprolol on Cardiac Function, Cardiac Remodeling, and Endothelial Function in Patients With Coronary Heart Disease and Heart Failure. British journal of hospital medicine (London, England: 2005), 86(4), 1–16. https://doi.org/10.12968/hmed.2025.0120
Sharfo, A., Lahn Sørensen, A., Eik Nielsen, E., Raymond, I. E., Boas Soja, A. M., & Hecht Olsen, M. (2025). OPTIHEART: determinants and prognostic importance of optimal medical treatment in patients with heart failure with reduced ejection fraction discharged from a heart failure clinic from 2018 to 2020. Blood pressure, 34(1), 2481229. https://doi.org/10.1080/08037051.2025.2481229
Wang, G., Zhang, R., Li, X., Zuo, S., Zhang, B., Zhao, Y., Sun, S., Zhang, J., & Liu, X. (2025). Efficacy of sacubitril/valsartan on improving clinical symptoms in patients with acute myocardial infarction complicated with heart failure: a retrospective study. PeerJ, 13, e18873. https://doi.org/10.7717/peerj.18873
Ye, S., Guo, N., Li, J., Zhao, J., Zong, D., & Wang, L. (2025). Early sacubitril/valsartan therapy reduces ventricular remodeling and cardiac events in patients with acute anterior myocardial infarction. European journal of pharmacology, 1007, 178188. https://doi.org/10.1016/j.ejphar.2025.178188
Berge, K., Schirmer, H., Øvrebotten, T., Nahoui, H., Gullestad, L., Ingul, C. B., Hole, T., Mo, R., Larsby, K., Norekvål, T. M., Omland, T., Ørn, S., & Myhre, P. L. (2025). Improvements in medical therapy and prognosis for patients with HFrEF following the 2021 ESC HF guidelines. ESC heart failure, 12(5), 3343–3352. https://doi.org/10.1002/ehf2.15337
Appenzeller, F., Harm, T., Sigle, M., Aidery, P., Kreisselmeier, K. P., Baas, L., Goldschmied, A., Gawaz, M. P., & Müller, K. A. L. (2025). Left ventricular function improvement during angiotensin receptor-neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients. ESC heart failure, 12(2), 1151–1165. https://doi.org/10.1002/ehf2.15100
Copyright (c) 2026 Marcin Schulz, Karolina Osińska, Dawid Studziński, Michał Kulczak, Anna Kołcz, Agnieszka Morawa
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
